Science

The mechanisms underneath the headlines.

The 0.45 That Families Are Being Asked To Weigh

Lecanemab and donanemab clear amyloid and slow early Alzheimer's decline by a fraction of a point on an 18-point scale. Here is what that fraction looks like from a waiting room, and what the MRI schedule is for.

Thirty Years Filed Under Harmless

P3 was the leftover nobody studied, the scrap from the safe cut of amyloid chemistry. A UC Santa Cruz biochemist says the test tube evidence always said otherwise, and that the amyloid cascade needs a bigger cast list.

A Protein's Shape Makes the Trip Intact: Tau Keeps Its Fold in a New Brain

Scientists took tau filaments from the brains of people who had died with Alzheimer's disease or corticobasal degeneration, injected them into ordinary mice, and watched the new tau that grew there copy the original's atomic shape down to the fold. It is the first direct structural check on a long-standing idea: that these misfolded proteins spread the way a stamp spreads its pattern, not the way a rumor changes with each retelling.

A Year of Alzheimer's Findings, Assembled Into One Map

A 32-page review in Cell takes the last cycle's scattered discoveries, on amyloid, tau, microglia and APOE, and sets them in causal order. It is a synthesis, not new data, and most of the machinery it describes was traced in mice and dishes.

The slow waves that stopped traveling

A Nature Neuroscience study reports that in older adults with tau in the frontal cortex, the big slow waves of deep sleep stay put instead of sweeping across the brain, and that the stalling tracks with weaker overnight memory. It is an association, not a diagnosis.

Tau's escape route out of the lysosome, and the crew that tries to seal it

A new preprint from a Berkeley structural biology lab used cryo-electron tomography on cultured neurons and astrocytes and found no evidence that tau fibrils tear their way out of lysosomes. The compartments stayed intact. The leak, the authors argue, is something subtler. This is laboratory cell work, not peer reviewed, and not a treatment.

New Model Proposes Molecular Steps Behind Lewy Body Formation

A laboratory study in Communications Biology reports that disease-linked chemical changes expose a normally hidden sticky region of alpha-synuclein, letting it grab other proteins indiscriminately, a mechanism the authors call a 'Multifactorial Random Disorder Model.'

Trial pairs two dopamine-making genes in one brain infusion for Parkinson's

A phase 1 study delivered a single viral vector carrying both tyrosine hydroxylase and AADC genes into the striatum, aiming for cells that manufacture dopamine on their own rather than depending on oral levodopa. Twelve-month safety data are now published; the trial was not designed to prove the therapy works.

The map arrives before the medicine

A January 2026 review in the Journal of the American College of Cardiology lays out the biology that vascular dementia therapies are aiming at, and is candid that most of the aiming has not yet hit anything

Heart output tracked brain change, but only in APOE-e4 carriers

In 756 adults followed at Vanderbilt for up to 11 years, lower baseline cardiac output predicted faster medial temporal change on MRI in carriers of the Alzheimer's risk gene, and not in non-carriers. The study is observational and its authors say it needs replication.

A rare frontotemporal dementia protein is shown to seed its own spread

Three years after cryo-EM revealed TAF15 filaments in patient brains, a Nature Communications paper reports that brain-derived TAF15 aggregates can template new aggregates in cultured cells, and pins the behaviour on a handful of short sequence motifs. All of the work is in test tubes and cells, not in people.

Splicing atlas separates the ALS lesion from the FTD lesion

A reanalysis of more than 1,600 postmortem RNA sequencing samples reports that the aberrant splicing left behind by TDP-43 concentrates in oligodendrocytes in ALS and in neurons in FTD, a distinction with consequences for biomarkers and drug targets.

Two FTD Genes, One Fragment Stuck Inside the Lysosome

A Stanford preprint traces frontotemporal dementia's biggest gene and its biggest modifier to a single measurable lesion: a TMEM106B fragment piling up inside neurons' waste-disposal compartments. The work is in mice, stem cell derived neurons and donated brain tissue, and it has not been peer reviewed.

Vision tests outpaced genotype in a Parkinson's dementia cohort

A preprint posted on 6 March 2026, not yet peer reviewed, followed 450 people with Parkinson's and no dementia for a mean of 32.7 months. Baseline visual performance separated those who declined; APOE4 on its own did not, and the GBA1 signal rested on 24 carriers.

The gut's slow drift toward Parkinson's, read in three groups at once

A Nature Medicine study of 464 people in the UK and Italy finds that the gut bacteria of GBA1 variant carriers without symptoms sit halfway between healthy controls and people with Parkinson's. It is a snapshot, not a prophecy, but it is the clearest map yet of a question nobody has answered: why only about one carrier in five ever converts.

Study measures how blood and haem shut down the prion test RT-QuIC

Bench work with scrapie-positive sheep tissue finds the inhibition comes from damage to the assay's own protein substrate, not destruction of the prion seeds, and that whole blood is one of the few sample types still near inhibitory levels after a 1,000-fold dilution.

The dish that finally held a human prion

A UCL team reports a dividing human-prion cell line, EKV, that keeps sporadic CJD prions growing indefinitely and measures how much infectivity a sample carries in weeks rather than years. It works only for some patients' prions, and it is laboratory work, not treatment.